Literature DB >> 33555089

Preferences for thyroidectomy technique: Comparing traditional and transoral approaches.

Lena W Chen1, Niddal Assadi2, Lior Hefetz-Kirshenbaum2, Hanna Hong1, Christopher R Razavi1, Raymon H Grogan3, Ralph P Tufano1, Avi Khafif2, Jonathon O Russell1.   

Abstract

BACKGROUND: We investigated preferences between the transcervical and transoral thyroidectomy approach in the United States and Israel.
METHODS: An online survey assessing scar attitudes and surgical preferences, in English and Hebrew, was distributed on ThyCa.com and other platforms.
RESULTS: 928 and 339 responses from the United States and Israel cohorts, respectively, were analyzed. In both countries, individuals without prior thyroidectomy preferred a scarless approach when hypothetical risks equaled those of traditional thyroidectomy (77% United States, 76% Israel, p = 0.61). U.S. respondents without thyroidectomy had greater preference to avoid a scar and would pay more to do so than those with thyroidectomy (both p < 0.001). Many respondents with prior thyroidectomy still expressed interest in scarless alternatives (57% United States).
CONCLUSIONS: Populations in Israel and the United States prefer scarless thyroidectomy when risks equal the traditional approach. While individuals without prior thyroidectomy are more likely to favor a scarless option, former thyroidectomy patients may have preferred avoiding a scar.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  TOETVA; scarless surgery; surgical preferences; thyroidectomy; transoral thyroidectomy

Year:  2021        PMID: 33555089     DOI: 10.1002/hed.26627

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Time Heals Most Wounds - Perceptions of Thyroidectomy Scars in Patients With Thyroid Cancer.

Authors:  Kathy Bach; Samantha Prince; Susan C Pitt; Sarah Robbins; Nadine P Connor; Cameron Macdonald; Rebecca S Sippel; Kristin L Long
Journal:  J Surg Res       Date:  2021-11-16       Impact factor: 2.192

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.